Veradermics, Inc (MANE): R&D Expense
$62.06M
Year ended 2025-12-31
$75.82M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.06M | +166.6% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $23.28M | n/a | 2026-03-30, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Veradermics, Inc (MANE) | 2025-12-31 | $62.06M | +166.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $25.58M | -30.4% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $90.96M | +78.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $47.39M | +25.5% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $41.33M | -22.1% |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $44.84M | -18.9% |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $154.22M | +110.5% |
Compare MANE, CTMX, OVID, WHWK side by side · Screen every company in Pharmaceutical Preparations ↗